Bioclinica acquires clinical research company

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/maxsattana)
(Image: iStock/maxsattana)

Related tags: Clinical trial, Clinical research

The acquisition of Compass Research expands Bioclinica’s access to several specialized populations with neurodegenerative disorders and other diseases.

"The Compass Research acquisition marks Bioclinica’s entry into the U.S. investigator site network​," Bioclinica CEO, John Hubbard, told

Compass Research will become part of Bioclinica’s Research Network Division, which is part of the Global Clinical Research Business Segment. 

"The Bioclinica Research Network has sites on three continents with plans to rapidly expand in the United States and other areas​," added Hubbard.

The Orlando, Florida-based clinical research company’s position in the state – specifically its presence in the largest retirement community in the US – will provide Bioclinica with access to 179,000 elderly residents who could contribute to research, including arthritis, back, knee and hip pain, Alzheimer’s Disease, dementia, cardiovascular diseases, among others.

Compass Research has also curated a database​ through its physician network and affiliate practices with in-clinic recruiters, which includes nearly 80,000 potential subjects.

"This acquisition of Compass Research brings established, highly successful U.S. investigational sites into Bioclinica’s global research network​," said Hubbard.

According to Bioclinica, the leadership team at Compass will play a strategic role in the company’s research network expansion.

"Compass will be joining a global research network with sites in Latin America, Europe, and Asia and will be a driving force in Bioclinica’s expansion into the United States​," added Hubbard.

In addition to expanding the company’s research network, Hubbard said that the companies “see unique synergies​” with its Medical Imaging, Biomarkers​, eHealth Solutions, and Patient Recruitment-Retention teams.

As previously reported​, Bioclinica is actively partnering to provide innovative offering models and technologies.

Most recently, the company launched a new clinical trial management system (CTMS) for contract research organizations (CROs) and mid-market biopharma. It also announced​ an agreement to become ArisGlobal's preferred partner to support a "continuum of pharmacovigilance services​."

"As with our other recent acquisitions, the primary goal in the near term is for a successful integration, ensuring no disruption to ongoing projects​," explained Hubbard.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more


View more